Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single Arm, Open Label, Simon Two-Stage Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients: Evaluation of Impact of Germline Variants in APOBEC3B

NCT03989089 is registered in ClinicalTrials.gov with University of Malaya as lead sponsor.

NCT NCT03989089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03989089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single Arm, Open Label, Simon Two-Stage Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients: Evaluation of Impact of Germline Variants in APOBEC3B
Lead sponsor
University of Malaya
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 3, 2020
Completion date
December 1, 2026
Enrollment
44 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer